Survival of patients with hepatopulmonary syndrome related to cirrhotic and non-cirrhotic (schistosomiasis) portal hypertension.

IF 2.5 Q2 GASTROENTEROLOGY & HEPATOLOGY
Melissa M Rolim, Liana G Farsoun, Carlos F Luna, Brivaldo Markman-Filho, Paulo Querette, Edmundo P Lopes, Ana L Domingues
{"title":"Survival of patients with hepatopulmonary syndrome related to cirrhotic and non-cirrhotic (schistosomiasis) portal hypertension.","authors":"Melissa M Rolim, Liana G Farsoun, Carlos F Luna, Brivaldo Markman-Filho, Paulo Querette, Edmundo P Lopes, Ana L Domingues","doi":"10.4254/wjh.v17.i2.99134","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The hepatosplenic schistosomiasis (HSS) with portal hypertension can cause vascular complications such as hepatopulmonary syndrome (HPS). HPS increases the risk of mortality in patients with cirrhosis; however, there is no data on the mortality of patients with HSS and HPS.</p><p><strong>Aim: </strong>To perform a survival analysis of patients with HPS related to cirrhotic and non-cirrhotic (schistosomiasis) portal hypertension.</p><p><strong>Methods: </strong>From August 2023 to January 2024, medical records and the official mortality information service of 121 patients who participated in a cross-sectional study on HPS between 2010 and 2012 were analyzed. Survival curves were created using the Kaplan-Meier method, and comparisons were performed using the log-rank test. Cox regression models estimated the hazard ratios (HR).</p><p><strong>Results: </strong>Overall, data of 113 patients were analyzed; most (55.8%) had HSS and concomitant cirrhosis (HSS/cirrhosis). Meanwhile, HPS was present in 39 (34.5%) patients. Death occurred in 65 patients [57.5%; 95% confidence interval (CI): 48%-67%. The average time to death was lower in those with HPS when compared to those without HPS (3.37 years <i>vs</i> 5.65 years; <i>P</i> = 0.017). According to the cause of liver disease, patients with HSS/cirrhosis died earlier, and their risk of death was twice as high compared with patients with HSS without cirrhosis (HR: 2.17; 95%CI: 1.3-3.60; <i>P</i> = 0.003). Meanwhile, there were no differences when comparing the two groups with and without HPS (HR: 1.01; 95%CI: 0.59-1.73; <i>P</i> = 0.967).</p><p><strong>Conclusion: </strong>Patients with HSS and concomitant cirrhosis had a lower survival rate, but there was no difference in survival regardless of the presence of HPS.</p>","PeriodicalId":23687,"journal":{"name":"World Journal of Hepatology","volume":"17 2","pages":"99134"},"PeriodicalIF":2.5000,"publicationDate":"2025-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11866160/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"World Journal of Hepatology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4254/wjh.v17.i2.99134","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: The hepatosplenic schistosomiasis (HSS) with portal hypertension can cause vascular complications such as hepatopulmonary syndrome (HPS). HPS increases the risk of mortality in patients with cirrhosis; however, there is no data on the mortality of patients with HSS and HPS.

Aim: To perform a survival analysis of patients with HPS related to cirrhotic and non-cirrhotic (schistosomiasis) portal hypertension.

Methods: From August 2023 to January 2024, medical records and the official mortality information service of 121 patients who participated in a cross-sectional study on HPS between 2010 and 2012 were analyzed. Survival curves were created using the Kaplan-Meier method, and comparisons were performed using the log-rank test. Cox regression models estimated the hazard ratios (HR).

Results: Overall, data of 113 patients were analyzed; most (55.8%) had HSS and concomitant cirrhosis (HSS/cirrhosis). Meanwhile, HPS was present in 39 (34.5%) patients. Death occurred in 65 patients [57.5%; 95% confidence interval (CI): 48%-67%. The average time to death was lower in those with HPS when compared to those without HPS (3.37 years vs 5.65 years; P = 0.017). According to the cause of liver disease, patients with HSS/cirrhosis died earlier, and their risk of death was twice as high compared with patients with HSS without cirrhosis (HR: 2.17; 95%CI: 1.3-3.60; P = 0.003). Meanwhile, there were no differences when comparing the two groups with and without HPS (HR: 1.01; 95%CI: 0.59-1.73; P = 0.967).

Conclusion: Patients with HSS and concomitant cirrhosis had a lower survival rate, but there was no difference in survival regardless of the presence of HPS.

肝硬化和非肝硬化(血吸虫病)门静脉高压症相关肝肺综合征患者的生存率。
背景:肝脾型血吸虫病合并门静脉高压症可引起肝肺综合征(HPS)等血管并发症。HPS增加肝硬化患者的死亡风险;然而,没有关于HSS和HPS患者死亡率的数据。目的:对肝硬化和非肝硬化(血吸虫病)门静脉高压症相关的HPS患者进行生存分析。方法:对2010 - 2012年参加HPS横断面研究的121例患者的病历和官方死亡信息服务进行分析。采用Kaplan-Meier法绘制生存曲线,采用log-rank检验进行比较。Cox回归模型估计了风险比(HR)。结果:共分析113例患者资料;多数患者(55.8%)伴有HSS和肝硬化(HSS/肝硬化)。同时,39例(34.5%)患者出现HPS。死亡65例[57.5%];95%置信区间(CI): 48% ~ 67%。与没有HPS的患者相比,HPS患者的平均死亡时间更短(3.37年vs 5.65年;P = 0.017)。根据肝病的病因,合并HSS/肝硬化的患者死亡时间较早,死亡风险是合并HSS无肝硬化患者的2倍(HR: 2.17;95%置信区间:1.3—-3.60;P = 0.003)。同时,两组在有无HPS的情况下比较无差异(HR: 1.01;95%置信区间:0.59—-1.73;P = 0.967)。结论:HSS合并肝硬化患者的生存率较低,但无论是否存在HPS,生存率均无差异。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
World Journal of Hepatology
World Journal of Hepatology GASTROENTEROLOGY & HEPATOLOGY-
CiteScore
4.10
自引率
4.20%
发文量
172
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信